Clinical research progress in novel drug NK3R antagonists for vasomotor symptoms in menopausal women
ZHENG Lian
WU Yue
LI Mei
HOU Ying-ying
Abstract：Vasomotor symptoms(VMS)are the hallmark symptom of menopausal women.Menopausal hormone therapy(MHT),the first-line treatment for VMS,has been limited in some target populations due to concerns about its venous thromboembolic risk and breast safety.Neurokinin 3 receptor(NK3R)antagonists are a new type of non-hormonal oral drug for the treatment of VMS in menopausal women.They prevent the over-activation of kisspeptin/neurokinin B/dynorphin(KNDy)neurons by blocking the binding of neurokinin B(NKB)to KNDy neurons,reduce the sensitivity of hypothalamic thermoregulatory centers,and restore normal thermoregulatory function,thus reduce the frequency and severity of hot flushes and night sweats.In this article,we will focus on reported NK3R antagonists and their clinical value in the treatment of VMS.
Keywords：vasomotor symptomsmenopausal womenhot flushesneurokinin 3 receptor antagonistfezolinetant
Publication Date：2025-08-03
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：7( 1735-1741 )